Up­dat­ed: GSK taps Chi­nese part­ner to ramp up Shin­grix sales in $3.05B deal, with op­tion to ex­pand to RSV

GSK is tap­ping a heavy­weight part­ner to co-pro­mote its block­buster shin­gles vac­cine Shin­grix in Chi­na — and lock­ing in £2.5 bil­lion ($3.05 bil­lion) over the next three years.

Its new part­ner, Chongqing Zhifei Bi­o­log­i­cal Prod­ucts, is the largest Chi­nese vac­cine com­pa­ny by rev­enue, GSK not­ed. While the phar­ma gi­ant pre­vi­ous­ly had ac­cess to around 9,500 points of vac­ci­na­tion, Zhifei’s ser­vice net­work cov­ers 30,000, ac­cord­ing to a GSK spokesper­son, mark­ing a sig­nif­i­cant ramp-up.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.